Bush Jennifer sold $57K of ARTV

Bush Jennifer (COO, CLO, Compliance Officer) sold 8,370 shares of Artiva Biotherapeutics, Inc. (ARTV) at $6.84 on 2026-10-05.

Original reporting
SEC EDGAR · Bush Jennifer
Published Oct 6, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
high confidence
Mentioned
$ARTV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock materially.

02

Market read

A small insider sale with limited trading relevance.

03

What to watch

Potential tax planning or portfolio rebalancing could drive the sale.

Relevance 3/10Novelty 3/10Timing: after-hours filing

Background

Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$ARTVNeutralHigh confidence
Context

COO Jennifer Bush sold 8,370 shares for $57,227, a Form 4 insider sale disclosed on 2026-10-06.

Expected impact

likely slight pressure as the market prices in the insider sell.

Evidence & confidence

The sale amount is small relative to holdings and market cap, so impact is limited.

Market effects

None significant for the biotech sector.

No broader regional effect.

Limited to ARTV investors.

Counterpoint

The sale may be routine and not indicative of future performance.

Key entities

  • Jennifer Bush

    COO, CLO, and Compliance Officer of Artiva Biotherapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.